ProCE Banner Activity

Key HIV Studies Influencing My Practice Following IDWeek and HIV Glasgow 2022—Chloe Orkin, MBChB, FRCP, MD, and Babafemi Taiwo, MBBS

Multimedia

Hear from expert faculty as they present their insights on some of the most clinically relevant new data presented at IDWeek and HIV Glasgow 2022, including prevention strategies, long-acting therapies, and investigational agents.

Released: November 30, 2022

Share

Faculty

Chloe Orkin

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities
Dean for Healthcare Transformation
Queen Mary University of London
Faculty of Medicine and Dentistry
London, United Kingdom

Babafemi Taiwo

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities
Dean for Healthcare Transformation
Queen Mary University of London
Faculty of Medicine and Dentistry
London, United Kingdom

Chloe Orkin, MBChB, FRCP, MD: consultant/advisor/speaker: Gilead Sciences, Janssen, MSD, ViiV Healthcare; researcher: AstraZeneca, Gilead Sciences, Janssen, MSD, ViiV Healthcare.

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS: consultant/advisor/speaker: Gilead Sciences, Johnson & Johnson, ViiV Healthcare.